Is TNGX or FBRX more profitable?

Tango Therapeutics' return on equity of -41.54% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Forte Biosciences N/A -106.17% -85.50%

Does the media favor TNGX or FBRX?

In the previous week, Tango Therapeutics and Tango Therapeutics both had 7 articles in the media. Tango Therapeutics' average media sentiment score of 0.81 beat Forte Biosciences' score of 0.64 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, FBRX or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is FBRX or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Parabilis Medicines N/A N/A N/A

Which has higher valuation and earnings, FBRX or VKTX?

Forte Biosciences is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A

Is FBRX or VKTX more profitable?

Viking Therapeutics' return on equity of -94.56% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Viking Therapeutics N/A -94.56% -82.75%

Does the media refer more to FBRX or VKTX?

In the previous week, Viking Therapeutics had 5 more articles in the media than Forte Biosciences. MarketBeat recorded 12 mentions for Viking Therapeutics and 7 mentions for Forte Biosciences. Viking Therapeutics' average media sentiment score of 1.12 beat Forte Biosciences' score of 0.64 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or FBRX more profitable?

Denali Therapeutics' return on equity of -53.53% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -53.53% -44.26% Forte Biosciences N/A -106.17% -85.50%

Does the media refer more to DNLI or FBRX?

In the previous week, Denali Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 13 mentions for Denali Therapeutics and 7 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.64 beat Denali Therapeutics' score of 0.22 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FBRX or RLAY more profitable?

Relay Therapeutics' return on equity of -47.23% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Relay Therapeutics N/A -47.23% -43.10%

Does the media favor FBRX or RLAY?

In the previous week, Relay Therapeutics had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 8 mentions for Relay Therapeutics and 7 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.64 beat Relay Therapeutics' score of 0.39 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Forte Biosciences (FBRX) Competitors

$76.79 -0.04 (-0.05%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$76.79 0.00 (0.00%)

As of 08/7/2026 07:34 PM Eastern

Compare

FBRX vs. TNGX, PBLS, VKTX, DNLI, and RLAY

Should you buy Forte Biosciences stock or one of its competitors? MarketBeat compares Forte Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forte Biosciences include Tango Therapeutics (TNGX), Parabilis Medicines (PBLS), Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), and Relay Therapeutics (RLAY). These companies are all part of the "biotechnology" industry.

How does Forte Biosciences compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Forte Biosciences (NASDAQ:FBRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Forte Biosciences has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	62.77	-$101.59M	-$0.83	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Tango Therapeutics' return on equity of -41.54% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Forte Biosciences	N/A	-106.17%	-85.50%

Tango Therapeutics presently has a consensus target price of $42.15, indicating a potential upside of 55.72%. Forte Biosciences has a consensus target price of $72.50, indicating a potential downside of 5.59%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Tango Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market.

In the previous week, Tango Therapeutics and Tango Therapeutics both had 7 articles in the media. Tango Therapeutics' average media sentiment score of 0.81 beat Forte Biosciences' score of 0.64 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tango Therapeutics beats Forte Biosciences on 10 of the 13 factors compared between the two stocks.

How does Forte Biosciences compare to Parabilis Medicines?

Forte Biosciences (NASDAQ:FBRX) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Forte Biosciences presently has a consensus price target of $72.50, suggesting a potential downside of 5.59%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 19.12%. Given Parabilis Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Parabilis Medicines is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Parabilis Medicines' return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Parabilis Medicines	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

In the previous week, Forte Biosciences had 7 more articles in the media than Parabilis Medicines. MarketBeat recorded 7 mentions for Forte Biosciences and 0 mentions for Parabilis Medicines. Forte Biosciences' average media sentiment score of 0.64 beat Parabilis Medicines' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Positive
Parabilis Medicines	Neutral

Summary

Parabilis Medicines beats Forte Biosciences on 6 of the 10 factors compared between the two stocks.

How does Forte Biosciences compare to Viking Therapeutics?

Forte Biosciences (NASDAQ:FBRX) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Forte Biosciences presently has a consensus target price of $72.50, suggesting a potential downside of 5.59%. Viking Therapeutics has a consensus target price of $97.88, suggesting a potential upside of 185.68%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Viking Therapeutics had 5 more articles in the media than Forte Biosciences. MarketBeat recorded 12 mentions for Viking Therapeutics and 7 mentions for Forte Biosciences. Viking Therapeutics' average media sentiment score of 1.12 beat Forte Biosciences' score of 0.64 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Forte Biosciences has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Forte Biosciences is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Viking Therapeutics' return on equity of -94.56% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Viking Therapeutics	N/A	-94.56%	-82.75%

Summary

Viking Therapeutics beats Forte Biosciences on 10 of the 14 factors compared between the two stocks.

How does Forte Biosciences compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Forte Biosciences (NASDAQ:FBRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Denali Therapeutics' return on equity of -53.53% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-53.53%	-44.26%
Forte Biosciences	N/A	-106.17%	-85.50%

Denali Therapeutics currently has a consensus price target of $35.92, suggesting a potential upside of 44.65%. Forte Biosciences has a consensus price target of $72.50, suggesting a potential downside of 5.59%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Denali Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Denali Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 13 mentions for Denali Therapeutics and 7 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.64 beat Denali Therapeutics' score of 0.22 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forte Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market.

Forte Biosciences has lower revenue, but higher earnings than Denali Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.92	-$512.54M	-$2.84	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Summary

Denali Therapeutics beats Forte Biosciences on 11 of the 14 factors compared between the two stocks.

How does Forte Biosciences compare to Relay Therapeutics?

Forte Biosciences (NASDAQ:FBRX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Forte Biosciences has higher earnings, but lower revenue than Relay Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Relay Therapeutics	$10.35M	365.96	-$276.48M	-$1.57	N/A

Relay Therapeutics' return on equity of -47.23% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Relay Therapeutics	N/A	-47.23%	-43.10%

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Forte Biosciences currently has a consensus price target of $72.50, indicating a potential downside of 5.59%. Relay Therapeutics has a consensus price target of $25.17, indicating a potential upside of 27.30%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Relay Therapeutics had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 8 mentions for Relay Therapeutics and 7 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.64 beat Relay Therapeutics' score of 0.39 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Summary

Relay Therapeutics beats Forte Biosciences on 12 of the 15 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBRX vs. The Competition

Export

Metric	Forte Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.07B	$3.69B	$7.02B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-16.55	9.02	271.11	25.19
Price / Sales	N/A	1,269.90	590.84	78.19
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	16.30	18.10	13.25	6.22
Net Income	-$69.38M	-$13.25M	$3.45B	$342.66M
7 Day Performance	0.25%	6.24%	4.67%	4.41%
1 Month Performance	109.24%	-3.50%	-1.28%	-1.10%
1 Year Performance	654.32%	61.28%	77.33%	23.99%

Forte Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBRX Forte Biosciences	1.3936 of 5 stars	$76.79 -0.1%	$72.50 -5.6%	+654.3%	$1.07B	N/A	N/A	5	Upcoming Earnings
TNGX Tango Therapeutics	2.5157 of 5 stars	$29.36 +7.9%	$42.15 +43.6%	+309.5%	$4.25B	$62.38M	N/A	90	News Coverage Upcoming Earnings
PBLS Parabilis Medicines	2.4682 of 5 stars	$35.90 +5.7%	$41.67 +16.1%	N/A	$4.24B	N/A	N/A	N/A	Positive News
VKTX Viking Therapeutics	3.5261 of 5 stars	$32.94 +1.0%	$97.88 +197.1%	-9.6%	$3.84B	N/A	N/A	20	Positive News
DNLI Denali Therapeutics	2.7138 of 5 stars	$24.17 +4.4%	$35.17 +45.5%	+77.9%	$3.84B	$330.53M	N/A	430	News Coverage Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBRX) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forte Biosciences (FBRX) Competitors

FBRX vs. TNGX, PBLS, VKTX, DNLI, and RLAY

How does Forte Biosciences compare to Tango Therapeutics?

Summary

How does Forte Biosciences compare to Parabilis Medicines?

Summary

How does Forte Biosciences compare to Viking Therapeutics?

Summary

How does Forte Biosciences compare to Denali Therapeutics?

Summary

How does Forte Biosciences compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forte Biosciences (FBRX) Competitors

FBRX vs. TNGX, PBLS, VKTX, DNLI, and RLAY

How does Forte Biosciences compare to Tango Therapeutics?

Which has preferable earnings & valuation, TNGX or FBRX?

Is TNGX or FBRX more profitable?

Do analysts prefer TNGX or FBRX?

Which has more volatility and risk, TNGX or FBRX?

Does the media favor TNGX or FBRX?

Do insiders and institutionals believe in TNGX or FBRX?

Summary

How does Forte Biosciences compare to Parabilis Medicines?

Do institutionals and insiders have more ownership in FBRX or PBLS?

Do analysts rate FBRX or PBLS?

Is FBRX or PBLS more profitable?

Which has stronger valuation and earnings, FBRX or PBLS?

Does the media favor FBRX or PBLS?

Summary

How does Forte Biosciences compare to Viking Therapeutics?

Do analysts recommend FBRX or VKTX?

Does the media refer more to FBRX or VKTX?

Do insiders and institutionals hold more shares of FBRX or VKTX?

Which has more risk & volatility, FBRX or VKTX?

Which has higher valuation and earnings, FBRX or VKTX?

Is FBRX or VKTX more profitable?

Summary

How does Forte Biosciences compare to Denali Therapeutics?

Do institutionals & insiders hold more shares of DNLI or FBRX?

Is DNLI or FBRX more profitable?

Do analysts recommend DNLI or FBRX?

Does the media refer more to DNLI or FBRX?

Which has more volatility & risk, DNLI or FBRX?

Which has preferable earnings & valuation, DNLI or FBRX?

Summary

How does Forte Biosciences compare to Relay Therapeutics?

Which has higher valuation and earnings, FBRX or RLAY?

Is FBRX or RLAY more profitable?

Do insiders & institutionals have more ownership in FBRX or RLAY?

Do analysts recommend FBRX or RLAY?

Does the media favor FBRX or RLAY?

Which has more volatility and risk, FBRX or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools